Themis Medicare Ltd
NSE: THEMISMED BSE: 530199Pharma
Themis Medicare Ltd (THEMISMED) is a Pharma company listed on NSE: THEMISMED | BSE: 530199. With a market cap of ₹897 Cr and ROCE of 11%, ROE of 7.7%, it operates in the Indian Pharma sector.
₹97.4
52W: ₹65 — ₹179
PE 0 · Book ₹32 · +204% vs bookMarket Cap₹897 Cr
Stock P/E—Price to Earnings
ROCE11%Return on Capital
ROE7.7%Return on Equity
Div. Yield0.51%Face Value ₹1
Weaknesses
- −Stock is trading at 3.01 times its book value
- −Company has low interest coverage ratio.
- −Company has a low return on equity of 10.6% over last 3 years.
- −Company has high debtors of 160 days.
Shareholding Pattern
Promoters67.1%
FIIs0.11%
DIIs0.01%
Public32.78%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.1%▼0.1 | 67.1% |
| FIIs | 0.05% | 0.1%▲0.1 | 0.1% | 0.14%▲0.0 | 0.09%▼0.1 | 0.06%▼0.0 | 0.05%▼0.0 | 0.11%▲0.1 |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 32.79% | 32.74%▼0.0 | 32.75%▲0.0 | 32.7%▼0.0 | 32.75%▲0.0 | 32.77%▲0.0 | 32.84%▲0.1 | 32.78%▼0.1 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 104.78 | 82.51 | 75.52 | 122.99 | 117.01 | 93.81 | 71.7 | 97.58 | 77.99 | 90.13 |
| Expenses | 92.37 | 74.44 | 67.04 | 93.81 | 99.89 | 85.28 | 77.48 | 107.67 | 81.09 | 80.32 |
| Operating Profit | 12.41 | 8.07 | 8.48 | 29.18 | 17.12 | 8.53 | -5.78 | -10.09 | -3.1 | 9.81 |
| OPM % | 11.84% | 9.78% | 11.23% | 23.73% | 14.63% | 9.09% | -8.06% | -10.34% | -3.97% | 10.88% |
| Net Profit | 7.1 | 2 | 3.09 | 18.71 | 9.87 | 3.08 | -7.74 | -15.37 | -5.36 | 4.58 |
| EPS ₹ | 0.77 | 0.22 | 0.34 | 2.03 | 1.07 | 0.33 | -0.84 | -1.67 | -0.58 | 0.5 |
AI Insights
Revenue Trend
TTM revenue at ₹337Cr, down 17% YoY. OPM at -3%.
Debt Position
Borrowings at ₹96Cr. Debt-to-equity ratio: 0.34x. Healthy balance sheet.
Capex Cycle
CWIP at ₹3Cr (2% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 0.01% (+0.00pp change). FIIs: 0.11% (+0.07pp change). Promoters hold 67.1%.
Margin & Efficiency
ROCE improving from 10% (Mar 2014) to 11% (Mar 2025). Working capital days: 123.
Recent Announcements
- Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 12 May - Company obtained valuation report and updated compliance certificate for preferential convertible warrant allotment.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Apr - Newspaper Publication of Notice to Shareholders for Special Window for re-lodgement of transfer request and dematerialization of physical shares.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 28 Mar - Postal ballot (27 Mar 2026): four resolutions passed, including Rs130 crore inter‑se transfer and preferential convertible warrants.
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 28 Mar - Postal ballot (27-Mar-2026): four resolutions passed, material related-party transactions and preferential warrants; GTBL transfer up to Rs.130 crore.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse